Clinical trials: Localized or Locally Advanced Prostate Cancer
- Condition Localized or Locally Advanced Prostate Cancer
- Funder type Industry (pharma, biotech, devices)
Localized or Locally Advanced Prostate Cancer
A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer
This study is a multi-centre, prospective observational study. The study plans to enrol 500 patients with localized or locally advanced prostate cancer who are eligible and intended to be prescribed Zoladex® (goserelin acetate…
- Trial name
- NCT03193060
- Where
- 25 sites in China
- Volunteers
- 308 people
- Sponsor
- AstraZeneca
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic…
- Trial name
- NCT05009290
- Testing
- SHR3680
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostatic Neoplasms
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk…
- Trial name
- PROTEUS (NCT03767244)
- Testing
- Apalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 2,517 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT)…
- Trial name
- NCT02531516
- Testing
- Apalutamide, Bicalutamide, GnRH (agonist)
- Where
- 263 sites in United States, Argentina and 21 more
- Volunteers
- 1,503 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
2 Years PSA Recurrence Rate
Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.
The primary objective is to assess the efficacy of immediate postoperative adjuvant hormonal treatment according to 2 year PSA recurrence rate in high risk localised or locally advanced Chinese prostate cancer patients.The…
- Trial name
- NCT01123434
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca